Related Experiment Video

Updated: Jul 2, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

DAPK1: a Novel Pathology and Treatment Target for Alzheimer's Disease

Ling-Zhi Xu1,2,3,4,5,6, Bing-Qiu Li1,2,3,4,5,6, Jian-Ping Jia7,8,9,10,11,12

  • 1Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, People's Republic of China.

Molecular Neurobiology
|August 1, 2018
PubMed

Insights

Death-associated protein kinase 1 (DAPK1) variants are linked to Alzheimer's disease (AD) risk. Exploring DAPK1's role in neurodegeneration may reveal new therapeutic targets for AD.

Area of Science:

  • Neuroscience
  • Genetics
  • Pathology

Background:

  • Alzheimer's disease (AD) is a leading cause of neurodegeneration in the elderly.
  • Current AD treatments targeting amyloid-beta and tau proteins have limited efficacy.
  • Complex, multifactorial pathogenesis of AD necessitates exploring novel contributing factors.

Purpose of the Study:

  • To review the current understanding of Death-associated protein kinase 1 (DAPK1) in Alzheimer's disease.
  • To explore DAPK1's genetic associations, neuropathological roles, and therapeutic potential in AD.

Main Methods:

  • Comprehensive literature review of studies on DAPK1 and Alzheimer's disease.
  • Analysis of genetic association studies linking DAPK1 variants to AD risk.
  • Examination of DAPK1's involvement in AD-related neuropathological processes.

Main Results:

  • Evidence suggests DAPK1 variants are associated with increased risk of developing AD.
  • DAPK1 activation is implicated in AD-related neurodegenerative processes within the brain.
  • DAPK1 plays a significant role in neuronal injury models.

Conclusions:

  • DAPK1 represents a potential genetic risk factor for Alzheimer's disease.
  • Understanding DAPK1's function in neurodegeneration is crucial for elucidating AD pathogenesis.
  • DAPK1 may serve as a promising novel therapeutic target for AD treatment.
Keywords:
Alzheimer’s diseaseDeath-associated protein kinase 1NeuropathologyTherapeuticsVariants

More Related Videos

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...